Claims:

1. Use of CHP to inhibit key targets selected from the group comprising collagen IV and/or glutathione S transferase (GST).

2. The use according to claim 1,
characterized in that
inhibition is effected *in vitro* or *in vivo*.

3. The use according to claim 1 or 2,
characterized in that
CHP is prepared and/or used in the form of a gel, poudrage, powder, tablet, sustained-release tablet, premix, emulsion, brew-up formulation, infusion solution, drops, concentrate, granulate, syrup, pellet, bolus, capsule, aerosol, spray and/or inhalant.

4. The use according to any of claims 1 to 3,
characterized in that
CHP is present in a formulation at a concentration of from 0.1 to 99.5, preferably from 0.5 to 95, and more preferably from 1 to 80 wt.-%.

5. The use according to any of claims 3 or 4,
characterized in that
infusion solutions with 1 to 2 wt.-% CHP are used.

6. The use according to any of claims 1 to 5,
characterized in that

CHP is employed in overall amounts of from 0.05 to 1000 mg per kg body weight, preferably from 5 to 450 mg per kg body weight per 24 hours.

7. Use of CHP in the production of collagen IV inhibitors and/or glutathione S transferase inhibitors for the treatment of autoimmune diseases, tumors, infections, metabolic diseases, neurological diseases, inflammatory reactions, scleroderma, vascular diseases, and diseases wherein reconstruction of connective tissue is effected, preferably fibroses.

8. A method for the inhibition of glutathione S transferase and/or collagen IV in an *in vivo* or *in vitro* system, characterized in that
the system is contacted with CHP.

9. The method according to claim 8, characterized in that
contacting in the event of *in vivo* systems is effected orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly, regionally, intraperitoneally and/or topically.

10. An anti-collagen IV and/or anti-GST agent, characterized in that
it comprises CHP, optionally together with a pharmaceutically tolerable carrier.

11. The agent according to claim 10, characterized in that
the carrier is selected from the group comprising fillers, diluents, binders, humectants, disintegrants, dissolution

retarders, absorption enhancers, wetting agents, adsorbents and/or lubricants.

12. The agent according to claim 10 or 11,
characterized in that
the carriers are liposomes, siosomes and/or niosomes.